Normal development of neuronal networks requires a delicate balance of proliferation and differentiation of specific neuronal lineages, and appropriate migration and integration of these specific neuronal subtypes into neuronal circuits. The development of neuronal circuitry and the human brain has intrigued scientists for generations, yet we have been unable to explore the development of human-specific neural networks because of limitations in current methodologies. Much of our understanding of normal brain development comes from the study of neurodevelopmental disorders, in which critical developmental pathways are disrupted. However, with emerging techniques that use human induced pluripotent stem cells (hiPSCs), the diseasealtered trajectory of early brain development can be reproduced while retaining a patient's unique genetic signature, enabling us to disentangle the contribution of genetic and nongenetic factors to the construction of normal and diseased neuronal circuitry.
Normal development of neuronal networks requires a delicate balance of proliferation and differentiation of specific neuronal lineages, and appropriate migration and integration of these specific neuronal subtypes into neuronal circuits. The development of neuronal circuitry and the human brain has intrigued scientists for generations, yet we have been unable to explore the development of human-specific neural networks because of limitations in current methodologies. Much of our understanding of normal brain development comes from the study of neurodevelopmental disorders, in which critical developmental pathways are disrupted. However, with emerging techniques that use human induced pluripotent stem cells (hiPSCs), the diseasealtered trajectory of early brain development can be reproduced while retaining a patient's unique genetic signature, enabling us to disentangle the contribution of genetic and nongenetic factors to the construction of normal and diseased neuronal circuitry.
Here, we discuss the biological and experimental challenges associated with hiPSC derivation, and review the applications of hiPSC-derived neuronal cells for modelling neurodevelopmental diseases. We begin by discussing the current understanding of neurodevelopmental disorders on the basis of neuroimaging, genetic and pathological studies. We then consider the shortcomings of such studies and the potential of hiPSCs to overcome these difficulties and advance our understanding of neurodevelopmental disorders, before discussing the mechanics of building hiPSC model systems and providing a comprehensive overview of existing hiPSC models of neurodevelopmental disorders.
Investigating neurodevelopmental disorders
Neurodevelopmental disorders include a range of conditions in which development of the CNS is altered so that acquisition and processing of sensory, motor and cognitive information in postnatal development is abnormal. In turn, modification of neural networks by ongoing neuronal activity is affected, resulting in a wide spectrum of emotional, cognitive and motor deficits, such as impaired language and/or nonverbal communication, impaired memory and learning, and motor dysfunction. insight into neurodevelopmental disorders, but are limited by their lack of complexity relative to the human brain, especially the human cortex. Mice and rats have fewer neurons than humans by an estimated 3-4 orders of magnitude 1 , and, owing to nonlinear scaling of neuronal density and connections with brain size, the development and structure of the human brain differs considerably from those of a rodent brain. Development of rodent brains is also much faster than that of the human brain. As a result, the prefrontal and temporal cortices, as well as the association areas interconnected with these regions, are more highly developed in humans than in rodents 2 ; these areas are often associated with higher cognitive functions, such as language, planning, logical thought, expression of personality and emotions, and are most relevant to neurodevelopmental disorders. The fact that few effective CNS-targeted drugs for neuro developmental disorders have been discovered via rodent models supports the idea that the models have limited validity [3] [4] [5] [6] . Human brain development has been studied by the analysis of postmortem tissue, but these samples offer only a single endpoint reading that provides little insight into the altered trajectory of early brain development in neurodevelopment disorders. Indeed, a large portion of the human genome is expressed in the developing brain 7 , so even if symptoms develop postnatally, all genetic developmental disorders are likely to involve prenatal structural and/or functional brain alterations.
Genetic studies have helped to confirm that some neurodevelopmental disorders, such as autism spectrum disorder (ASD) and schizophrenia, have a high heritability and risk of within-family recurrence [8] [9] [10] [11] . Improvements in genome sequencing have facilitated numerous genome-wide association studies, candidate gene discoveries and exome-sequencing studies [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] , but these genomic studies can only identify loci that contribute to disease risk, and they do not assess the functional consequences of genetic variants. Transcriptome analyses can assess these functional consequences to some degree, but are subject to environmental influence and other confounding variables. Furthermore, brain transcriptome studies cannot distinguish between primary causes and secondary consequences of disease. Ideally, therefore, genetic studies should involve simultaneous genome and transcriptome analyses in a disease-relevant tissue, and should not be limited by the availability of disease-relevant tissue in the form of autopsy specimens from patients with neurodevelopmental disorders 22 .
The potential of hiPSCs
Embryonic stem cells (ESCs) are the ideal experimental model for studying early brain development in humans, but several ethical issues prevent their use in this way. Furthermore, embryos with genetic defects are accessible to only a small number of laboratories, and the derivation of such ESC lines requires connection to a centre at which preimplantation genetic diagnosis is performed. The discovery of hiPSCs has provided an alternative model by enabling in vitro derivation of ESC-like cells from almost any type of somatic cell. Furthermore, unlike ESCs, hiPSCs can be generated from patients with defined clinical phenotypes, thus enabling in vitro phenotypes to be linked to the clinical presentation. The hiPSC model system shows great promise for overcoming many of the problems with animal, postmortem, genetic and ESC studies and for elucidating the pathogenesis of neurodevelopmental disorders.
Unlike postmortem human brain tissue, hiPSC model systems are actively developing and express dynamic genetic programmes that regulate cell proliferation and differentiation into neural precursors and, subsequently, mature neurons and glial cells. As gene expression changes dramatically at birth 23 , these systems provide a unique opportunity to study genetic programmes that are active in the prenatal brain. Furthermore, hiPSC systems are not distorted by other disease processes in the way that postmortem brain tissue is, eliminating the difficulty in distinguishing causes from consequences and experimental artefacts.
In principle, hiPSC model systems can recapitulate the progression of brain development from early embryogenesis day zero to various stages of maturity. One drawback is that hiPSC-derived brain cells are not as complex as those in the brain, and technical reasons currently limit our ability to grow these cells in vitro for long enough to recapitulate the perinatal and adult brain. Nevertheless, hiPSC-derived models can enable us to examine how aberrations in brain structure, composition and connectivity that are observed in postmortem and imaging studies arise and develop, and to derive quantifiable measures of neuronal morphology, function, electrophysiology, connectivity and gene expression from multiple timepoints during embryonic and fetal brain development (FIG. 1) .
Similarly, implementation of genome-scale deep-sequencing technologies with hiPSC model systems increases the potential of these systems to uncover
Key points
• Human induced pluripotent stem cells (hiPSCs) are essentially equivalent to embryonic stem cells (ESCs) in that they can differentiate into any adult cell; however, unlike ESCs, hiPSCs can be derived from any somatic cell • hiPSCs retain the unique genetic signature of the patient whose somatic cell they were derived from and, therefore, enable us to recapitulate the patient's early development in a dish • In the context of neurodevelopmental disorders, hiPSCs enable us to re-enact the altered trajectory of brain development in an individual with disease and simultaneously compare it with normal brain development • hiPSC models of neurodevelopmental disorders have not only confirmed the results of pre-existing pathological and genetic studies, they have also elucidated previously unknown facets of these disorders' underlying biology • In studying abnormal brain development, hiPSCs can be differentiated into cortical neurons, dopaminergic neurons, astrocytes, etc.; one can even derive 3D organoids in which several brain cell types and tissue layers develop from precursor cells • The holy grail of hiPSC models would be to use them as a drug discovery and/or screening platform for neurodevelopmental disorders; promisingly, studies have already made progress towards this goal
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Reprogramming Non random X inactivation the networks of genes underlying neurodevelopmental disorders. Genome-scale deep sequencing studies in hiPSC models can reveal the consequences of gene mutations on the entire cellular transcriptome, and, in turn, how changes in transcriptomics translate into cellular phenotypes. Genome engineering tech nologies should also help to determine which of the myriad developmental alterations are crucial for a given cellular and molecular phenotype. Although the cellular and molecular consequences of mutations can be explored in animal models and cultured human cell lines, hiPSC-derived modelling provides information that is immediately applicable to humans because hiPSCs have a specific human genetic background and, with sufficient sample sizes, can reveal how interindividual genetic variations influence phenotypes.
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Generation of hiPSC models
Generation of an hiPSC model requires two steps: reprogramming and differentiation. Reprogramming (also known as reverse-differentiation) involves the reversion of any somatic cell to its ESC-like state, known as the hiPSC state. Subsequent differentiation of the hiPSCs enables generation of the somatic cells required to model the disorder of interest; in the context of neurodevelopmental disorders, the required cell type is likely to be that of a specific brain region, neuronal network or neuronal subtype.
Reprogramming
The reprogramming process involves reactivation of genes in the somatic cell that are important in maintaining the characteristic pluripotent state of ESCs. 
Dual SMAD inhibition method
Method to achieve efficient neural induction of pluripotent stem cells by the synergistic action of two inhibitors of SMAD signalling: Noggin, an inhibitor of bone morphogenetic protein, and SB compound, an inhibitor of lefty-activin-TGFβ pathways.
Reprogramming is triggered by the introduction of key transcription factors, which leads to a unique 'open' chromatin profile [24] [25] [26] [27] [28] 
. The process is highly specific, intricate and inefficient; the efficiency is influenced by many factors, including bioenergetics, cell cycle regulators, microRNAs 29 and dosage of reprogramming factors 30 . Much less is understood about the cellular and molecular events necessary to initiate and maintain a pluripotent state than is understood about the initial reprogramming step of reverting a fully differentiated somatic cell to its undifferentiated state. We do know that several genes are activated and several developmental transcription factor cascades are consequently turned on. In-depth discussion of what we know about these processes is available elsewhere 31 . The process is far from perfect, and hiPSCs can retain some gene expression and chromatin modification patterns of their originator somatic cell, thereby biasing their differentiation towards the lineage of their originator cell lineage. Nevertheless, when genetic background, clonality and sex are controlled for, comparison of hiPSCs with ESCs has demonstrated no consistent differential gene expression or epigenetic signature, suggesting that human ESCs and hiPSCs are molecularly and functionally equivalent 32 .
Differentiation
Differentiation of hiPSCs into neuronal cells begins with neural induction mediated by appropriate concentrations and gradients of several morphogenetic factors that are normally expressed in the developing brain. For modelling of ASD, schizophrenia, intellectual disabilities and other disorders that primarily affect higher cognitive functions, several in vitro protocols have been developed with the goal of mimicking the development of the cerebral cortex. The mature cerebral cortex is a six-layered structure composed of two main classes of neurons: glutamatergic excitatory neurons and GABAergic inhibitory interneurons. Different subtypes of these neurons are located in different cortical layers. The fate specification and differentiation of the subtypes of cortical neurons is determined by the expression of specific combinations of transcription factors in each sub population. The strategy for neuronal differentiation of hiPSCs should, therefore, be chosen to mimic the appropriate differentiation process with the aim of understanding how it goes wrong in developmental disorders.
Monolayers versus organoids
The two main neuronal differentiation models of hiPSCs are monolayer cultures or 3D organoid cultures (FIG. 1) . For each of these models, several protocols have been developed and are continually being improved.
In general, monolayer neuronal cultures are derived from neuronal precursor cells that can be dissociated from each other during active division. Their population is subsequently expanded by repeated passaging under growth factor stimulation and cells can be frozen, providing a useful source for future experiments. The advantages of these types of cultures include the ability to obtain a large number of neuronal progenitor cells (NPCs) that can be differentiated into mature neurons, and relatively easy analysis of cellular morphology (such as neuronal branching and spine quantification) owing to the 2D nature of these in vitro systems. One of the most commonly used protocols for generating monolayer cultures of ESCs and hiPSCs is the dual SMAD inhibition method
33
. The original version of this protocol resulted in conversion of ESCs and hiPSCs to neuronal cells with an efficiency of >80%; an adaptation of the protocol has been used successfully to generate dopaminergic neurons to study Parkinson disease 34, 35 and to generate cortical interneurons 36 . An alternative protocol that combines dual SMAD inhibition with retinoid signalling has led to a 95% efficiency of neuronal differentiation 37 and has been used to model Alzheimer disease and schizophrenia [37] [38] [39] . Many more variations of 2D culture protocols exist that have been developed and successfully used to generate specific neuronal subtypes, such as GABAergic inhibitory neurons 40 , glutamatergic neurons 37 and hippocampal granule neurons 41 (Supplementary information S1 (table) ). The main disadvantage of monolayer neuronal cultures is that they lack the spatial organization of the brain. Moreover, the approaches to generating a monolayer culture confer highly unphysiological mechanical and adhesive properties to differentiating neurons, which alter neuronal morphology and gene expression. As a result, the quantity and types of neurons produced are highly dependent upon subtle variations in cell-to-cell contacts and interactions, which are in turn influenced by the initial plating density of the neuronal progenitors, the adhesive substrate, and the exogenous factors added to the preparation.
In the past 5 years, protocols for the generation of organoid cultures have been developed to overcome the drawbacks of monolayer cultures and to better mimic the 3D structure, organization, composition and connectivity of the human brain. The main difference in organoid cultures compared with monolayer cultures is that many membrane surfaces of cells are in direct contact with each other. Thus, organoid cultures enable recapitulation of a wider range and greater complexity . Open chromatin structure, or euchromatin, refers to a loose packing of the DNA around histone proteins in nucleosomes that enables easier access of transcription factors and other regulatory factors to the DNA template. The result is usually active transcription.
Reprogramming of a somatic cell into an hiPSC is a three-step process from an epigenetic perspective. In the first step, epigenetic and other transcription factors must work together to erase the somatic cell's current epigenetic state. Subsequently, they must establish a pluripotent epigenetic state in the cell. Finally, they must maintain this pluripotency as well as immortality (the ability for indefinite in vitro mitotic division). Lineage-committed somatic cells often have a relatively closed epigenetic state, with many highly condensed heterochromatin foci 28, [179] [180] [181] . The tight packing of DNA around histone proteins in nucleosomes restricts access of transcription factors to the DNA template and reduces overall transcriptional activity. The open epigenetic state in hiPSCs results in more active transcription.
of cellular interactions and morphogen gradients under minimally perturbed conditions. The preservation of cell-to-cell contacts enables the self-organization of progenitors and neurons into layers that resemble the mammalian forebrain in the early stages of development.
The advent of 3D cultures started with the pioneering work of Yoshiki Sasai and colleagues in 2008, in which they derived 3D organized aggregates of neuronal cells from mouse and human ESCs
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. This study also showed that addition of patterning factors to the culture medium enabled the regional identity of cortical neurons to be specified. Similar protocols were developed and optimized for the 3D differentiation of hiPSCs 43, 44 . In 2013, Lancaster and colleagues developed a method that was designed to generate organoids that mimic the organization of the entire brain; they used this method to model intrinsic neuronal differentiation defects in individuals with microcephaly 45 . Organoids generated with this method are heterogeneous in the sense that each organoid contains domains that mimic various brain regions (such as cerebral cortex, brainstem, retina and choroid plexus). We have developed 3D organoid cultures to study ASD
46
, and generated these cultures with a method that differed from those already discussed: this protocol involved initial enrichment of neural progenitor cells by manual selection of neural rosettes, which enables a more homogeneous differentiation of each organoid into dorsal and ventral neurons that mainly represent the telencephalon.
Important variables in hiPSC models
Among the variables that can influence the results of an hiPSC study, one of the most important is the quality of the hiPSC lines and the presence of epigenetic ab normalities and somatic mutations [47] [48] [49] [50] . Poor-quality hiPSC lines are more likely to fail or produce variable outcomes with any differentiation method, thereby complicating interpretation of the results. Good practice is to differentiate 2-3 different hiPSC lines for each individual in each experiment.
The second most important variable is the method of differentiation. Variables between differentiation protocols include the initial enrichment and selection of NPCs with different techniques, such as manual isolation, fluorescence-activated cell sorting or bead isolation, and whether NPCs are cultured in a monolayer or a 3D environment. For example, monolayer protocols typically involve a lower cell density, decreased cell-to-cell signalling and increased cell-to-matrix signalling than 3D protocols; these variables, along with matrix rigidity and stiffness, have all been shown to influence cell fate.
Regardless of the differentiation method used, appropriate analysis of the regional and cellular specificity of a neuronal differentiation protocol is imperative. Analysis of a few cellular markers is generally not sufficient for this purpose, and a better way to address this question is to perform global transcriptome analysis by classifying samples against rich and well-curated databases of the developmental transcriptome of the human brain, such as Brainspan
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. For example, in a study of a telencephalic organoid model of ASD 46 , a simple classification algorithm based on correlation analysis showed that the organoid's transcriptome best resembled that of human cortical brain development at 8-10 post-conceptional weeks, with weaker correspondence to later stages of fetal development, suggesting that the in vitro developmental timeline mimics early in vivo brain development. A sophisticated machine-learning algorithm called CoNTExT 52 has since been developed, which identified strong conservation of transcriptomic network signatures between primary human NPCs and the developing human fetal brain, but highlighted differences between these primary human NPCs and hiPSC-derived neural progenitors from multiple laboratories. CoNTExT has not yet been applied to transcriptome data derived from organoids, which might differ from neural progenitors that have been dissociated and grown in 2D culture.
Experimental design in hiPSC modelling
A variety of experimental designs are used for disease modelling with hiPSCs. In this section, we discuss designs that are only possible with hiPSC models, or for which hiPSC models offer distinct advantages over other existing modes of study, such as animal models, postmortem studies and genomic studies.
The matched pairs design is a widely used and powerful experimental design in which cases are matched to controls on the basis of one or more factors, which enables confounding variables (for example, sex, age and genetic background) to be controlled for at the design stage rather than the analysis stage. When the sample size is small, matching is more efficient than controlling for confounding factors during analysis if the cost of matching is lower than that of increasing the sample size. This scenario is certainly true in the case of hiPSC studies. On the downside, the required match cannot always be found, especially in the case of post mortem tissue samples, owing to the limited availability of covariate-matched tissue samples. The matched pairs design has been successfully applied to postmortem tissue studies [53] [54] [55] and to hiPSC studies 32, 56 . The family design can be considered a subclass of the matched pairs design in which the family (genetic) background is the controlled factor. This design has been used extensively in genomic studies to investigate genetic transmission within families; for example, to discover de novo mutations. This powerful approach was successfully implemented in an hiPSC-based ASD study 46 . However, the family design is not possible when using postmortem tissue. The advantage of using a family design in hiPSC studies is that it is well suited for use with small sample size: the design enables good control of genetic background effects, which drive a large portion of variability between hiPSC lines. One factor that might be expected to be a drawback in the family design is the age difference between probands and controls when children are the probands and their parents are the controls, as there could be an effect whereby the age of somatic cells persists as epigenetic memory in the hiPSC lines, potentially affecting their properties. However, studies have shown that the 'age signature' of the cell donor is reset by the reprogramming
Isogenic controls
Controls with identical genetic backgrounds as the experimental sample, except for the gene under investigation.
process for generating hiPSCs 57, 58 , whereas this reversal does not seem to occur when the somatic cell is directly converted into neurons 59 . As a result, hiPSCs that are derived from older donors do not exhibit clear differences in transcriptional signatures compared with those of cells derived from younger donors. Thus, an age difference between probands and controls is less of a concern when hiPSC-derived samples are compared than when samples of directly converted cells are compared. Another potential problem of the family design is that it cannot be used to study how phenotype is influenced by genetic risk factors that are shared by all family members. To mitigate this problem, the design should incorporate families with disease and families without, as is commonly done in genomic studies. Indeed, a distinct advantage of the family design is that its common use in genomics might facilitate the identification of correlations between genetic variation and phenotypes that are investigated with hiPSC modelling.
Finally, the isogenic design, in which isogenic controls are used, is increasingly being used for hiPSC studies, in which it is usually implemented to analyse the functional effects of genetic or epigenetic perturbations in the same cell line (see the hiPSC models of neurodevelopmental disease section). This study design is an extremely powerful approach as it enables, for instance, functional characterization of a genetic mutation by correcting it in cells from a patient that carries the mutation (for example, through genome engineering with CRISPRCas9 technology). As most of the variation between hiPSC lines is due to genetic background effects 32 , comparison between isogenic lines when investigating the phenotypic effect of single genes can be powerful. Yet, isogenic pairs do not completely resolve the issue of modelling disorders. One reason is that even in the so-called monogenic disorders, penetrance can vary substantially, depending on the genetic background. This pheno menon necessitates the investigation of mutations in multiple genetic backgrounds.
hiPSC models of neurodevelopmental disease hiPSCs have been used to model neuro developmental disorders in many studies (Supplementary information S1-S5 (tables)). In many cases, the models have confirmed or expanded our understanding of disease pathology that has been gained from neuroimaging, postmortem and rodent model studies. However, hiPSC models have enabled us to understand, for the first time, the cellular and molecular mechanisms that give rise to these disorders and drive their progression from the earliest stages of human development.
Engineering of specific disease-relevant penetrant mutations in hiPSCs is particularly powerful for the study of disorders in which such mutations exist (for example, mutation of FMR1 in fragile X syndrome and of TSC1/2 in tuberous sclerosis). However, hiPSCs can also be useful for studying complex genetic disorders, such as schizophrenia and ASD. Given sufficient sample size, derivation of hiPSCs from individuals with these complex diseases and from appropriate controls can be equally as powerful as that in monogenic diseases.
In this section, we discuss existing hiPSC-based models of neurodevelopmental disorders: both those that involve a single disease-penetrant mutation, and complex disorders in which hundreds of genes have been implicated. We define a neurodevelopmental disorder as one that alters the course of normal human brain develop ment and for which aetiological factors are influential in prenatal or early postnatal life. Such disorders include Rett syndrome, Timothy syndrome, fragile X syndrome, ASD and schizophrenia. Some evidence indicates that bipolar disorder has developmental origins 60 , and some prominent hiPSC studies of this disorder have been carried out [61] [62] [63] , but overall, the evidence does not conclusively point to a developmental aetiology, so we have not included discussion of models for this disorder.
Owing to the extent of resources and time required for hiPSC studies, some of the published studies include only one affected hiPSC line and one control line and do not include any genetic risk variant assessment. These studies probably add little conclusive evidence about disease pathology, so we have excluded them from our Review.
Penetrant mutations
The most extensive work in hiPSC modelling of neurodevelopmental disorders has been done in the context of the monogenic disorder Rett syndrome. However, the monogenic neurodevelopmental disorders fragile X syndrome and Timothy syndrome have also been studied with hiPSC models; the symptoms of both of these disorders include symptoms of ASD.
Rett syndrome. Classic Rett syndrome is characterized by an initial period of normal growth and development followed by a period of regression (the reversal of growth and development milestones that had been reached), followed by recovery or stabilization of growth rate. The diagnosis is usually considered when post natal deceleration of head growth is observed, though this sign might not be observed in all cases. Patients with Rett syndrome often exhibit partial or complete loss of acquired purpose ful hand skills and/or acquired spoken language. Often, these symptoms are accompanied by onset of gait abnormalities and stereotypical hand movements 64 . Rett syndrome almost exclusively affects women and is most often caused by X-linked mutations in the MECP2 gene, a transcription factor that is crucial for normal brain development. Rett syndrome is also associated with mutations in CDKL5 or FOXG1, though to a far lesser extent than MECP2.
Studies of brain pathology in Rett syndrome have provided evidence of decreased neuronal and brain size, defects in synaptogenesis, and reduced dendritic arborization and number of spines. Some studies have also identified altered (mostly reduced) neuro transmitter levels [65] [66] [67] . Gene expression profiling of postmortem samples of brains from patients with Rett syndrome have also hinted at specific deficits in expression of pre synaptic markers 68 . All of these signs indicate that neurons are less mature and less complex than healthy neurons. Defects in synaptogenesis can lead to alterations in neuronal
L1 retrotranspositions
Phenomena in which a segment of DNA (known as a retrotransposon) is transcribed into RNA and subsequently reverse-transcribed back into the original DNA sequence, which can be newly inserted into other parts of the genome.
Non-cell-autonomous disorder
A disorder in which mutant cells cause nonmutant cells to exhibit a mutant phenotype.
processes such as learning, memory and information retrieval 69 . Reduced dendritic arborization is a sign of a less complex neuron. Similarly, spine density on excitatory glutamatergic neurons is a strong indicator of the maturity of these neurons and their ability to potentiate synaptic connectivity, as dendrites with fewer spines receive fewer inputs. Furthermore, spine formation, plasticity and maintenance depend on contact-mediated and long-range signals that are genetically encoded to some extent, but are also regulated by synaptic activity and modulated by sensory experiences [70] [71] [72] , which are likely to be abnormal in patients with Rett syndrome. In combination, these observations imply the presence of a vicious cycle in Rett syndrome, whereby spine density and sensory experiences are both abnormal and each prevent development of the other.
The first derivation of Rett syndrome hiPSC lines with mutations in MECP2 was performed by Hotta et al. in 2009 (REF. 73 ) and, to our knowledge, the first of these models to undergo extensive phenotypic characterization was created in 2010 by Marchetto et al. 74 , who derived hiPSCs from the fibroblasts of patients with Rett syndrome with MECP2 mutations. They found that neurons derived from patients with mutations in MECP2 had fewer synapses, lower spine densities and smaller cell bodies than those derived from healthy controls (referred to as wild-type neurons throughout this Review). Furthermore, glutamatergic neurons in the model cultures had a lower density of the glutamate transporter VGLUT1. Knockdown of MECP2 in wildtype hiPSCs resulted in a similar glutamate transporter phenotype. Conversely, overexpression of MECP2 in wild-type neurons or neurons derived from patients with Rett syndrome resulted in increased density of VGLUT1, suggesting a dose-dependent relationship between MECP2 expression and glutamate transport. Interestingly, overexpression of MECP2 is also pathogenic, and a primate model of MECP2 overexpression exhibits ASD-like social deficits 75 . Similarly, an hiPSC model of MECP2 duplication syndrome has shown that cortical neurons derived from affected hiPSC lines have increased synaptogenesis and dendritic complexity, as well as altered neuronal network synchronization 76 . In addition to the effect on glutamate transport, knockdown of MECP2 in wild-type neurons led to decreased spine density and soma size, similar to the pathology that has previously been described in Rett syndrome and to that seen in neurons derived from patients with Rett syndrome. Neurons derived from patients with Rett syndrome also exhibited functional alterations at the neural network level: a decrease in the frequency of intracellular calcium oscillations and a decrease in the frequency and amplitude of spontaneous postsynaptic excitatory currents compared with wild-type neurons 74, 77 . Calcium has wide-ranging effects in neurons, from microsecond-level control of presynaptic neurotransmitter secretion to gene regulation in the nucleus, which can occur over hours or days. Calcium is also required for activity-dependent synaptic plasticity, a process crucial to learning and memory [78] [79] [80] [81] . The observed decreased frequency and amplitude of spontaneous postsynaptic excitatory currents in neurons derived from patients with Rett syndrome is consistent with the decrease in intracellular calcium transients, and reduces the likelihood of action potential firing. All these observations made in hiPSC-derived neurons would have been impossible to make in patients. From a translational perspective, the Marchetto et al. study produced promising results, as it showed that administration of insulin-like growth factor 1 (IGF1) and/or gentamicin rescued certain neuron cell defects, such as reduced VGLUT1 density 74, 77 . Several other studies [82] [83] [84] [85] [86] [87] [88] 74 and demonstrated small cell body size, deficits in neuronal maturation, and decreased dendritic complexity. One of these studies 88 also showed that neurons derived from patients with Rett syndrome had decreased cell capacitance and dysfunction in action potential generation, voltage-gated sodium currents, and miniature excitatory synaptic current frequency and amplitude. Two other studies provided particularly clear demonstrations of the power of hiPSCs by showing that neurons derived from patients with Rett syndrome had an increased frequency of L1 retrotranspositions 85 and a delay in the functional switch in GABA signalling from excitatory to inhibitory that normally occurs earlier in development 86, 89 , conclusions that would be almost impossible to derive from any other experimental system. The second of these studies further showed that IGF1 treatment rescued functional deficits in GABA signalling 86 . Models have also been generated with hiPSCs from patients with Rett syndrome who have rare mutations. For example, models with CDKL5 and FOXG1 mutations have been developed and reveal reduced numbers of synaptic contacts, aberrant spine structures, an increased tendency to differentiate into inhibitory synapses, and reduced levels of excitatory synaptic markers 87, [90] [91] [92] . In other studies in which Rett syndrome has been modelled 93, 94 , hiPSCs have been differentiated into astrocytes, and the results have suggested that MECP2 mutant astrocytes derived from patients with Rett syndrome have adverse effects on the morphology and function of wild-type neurons that were partially reversible with IGF1 treatment. Overall, the evidence suggests that Rett syndrome is a non-cell-autonomous disorder and that the effect of astrocytes on neuronal morphology is unrelated to the intrinsic neuronal deficit observed in Rett syndrome. One hiPSC model demonstrated that microtubule-dependent vesicle transport was altered in mutant astrocytes and that this alteration was reversible with epothilone D 93 . The fact that Rett syndrome is an X-linked disorder makes it more difficult to model than other monogenic disorders, owing to the phenomenon of somatic X chromosome inactivation
. Nevertheless, this phenomenon also creates the unique opportunity for an isogenic control because hiPSC lines derived from one patient with Rett syndrome could express either the mutant or wild-type allele. This opportunity has been exploited in several studies in which both mutant and isogenic control hiPSC lines have been derived from individuals with Rett syndrome 73, 82, 88, 95 . These studies have shown that neurons with the mutant MECP2 allele had a smaller soma than the isogenic control neurons expressing wild-type MECP2.
Fragile X syndrome. Fragile X syndrome is one of the most common causes of syndromic ASD, and often also causes moderate to severe intellectual disability, speech delays, growth and motor abnormalities, hyperactivity, and anxiety 96, 97 . Fragile X syndrome is thought to result from low expression of the FMR1 gene, which encodes FMRP, an RNA-binding protein that inhibits mRNA translation. Regulation of mRNA translation is thought to be important for synaptic plasticity and neuronal maturation, thus making the FMR1 gene crucial for brain development. Expansion of CGG repeats in the 5ʹ untranslated region of FMR1 results in hypermethylation and consequent silencing of the gene in an X-linked dominant manner. Healthy individuals have ~6-40 CGG repeats, whereas individuals with fragile X syndrome have >200-230 CGG repeats 98 . Excessive baseline levels of protein synthesis as a consequence of low FMR1 mean that protein synthesis that depends on synaptic activity is no longer regulated in this way, which in turn disrupts several higher cognitive processes, such as learning and speech development [99] [100] [101] . Without regulation of protein synthesis by synaptic activity, physical encoding of information in the brain cannot function fully.
hiPSC modelling of fragile X syndrome is as complicated as modelling of Rett syndrome. In a study of ESCs derived from embryos with the FMR1 mutation, FMR1 was expressed in the ESCs but underwent transcriptional silencing after differentiation 102 . A subsequent study identified a similar phenomenon in hiPSC modelling of fragile X syndrome: in hiPSCs generated by reprogramming of somatic fibroblasts from patients with the disorder, FMR1 had undergone epigenetic inactivation 103 
.
To our knowledge, only two groups 104, 105 have created hiPSC models of fragile X syndrome that enabled them to study the phenotype of neurons derived from patients. Both models revealed aberrant neuronal differentiation of the hiPSCs derived from patients and showed that the neurons that were generated had abnormally little outgrowth of neurites, and those that grew had few processes that were short, echoing findings from FMR1 knockout mouse models 106, 107 and studies of postmortem brain tissue 104, 105, 108 . In one study, the abnormal transcriptional signatures that might underlie the abnormalities were assessed and reversed through the introduction of an microRNA mimic into the cell 109 . Interestingly, the findings of these two groups imply that the condition involves early neurodevelopmental alterations that occur before synaptogenesis, although more studies are needed to fully understand the pathophysiology of these defects. In several studies, hiPSCs derived from patients with fragile X syndrome have been used to create proof-of-concept high-throughput drug discovery systems [110] [111] [112] [113] , although the sensitivity and robustness of these screens require considerable improvement. Promisingly, CRISPR-Cas9 genomic engineering
has been used to ablate CGG repeats in hiPSCs derived from patients with fragile X syndrome -this technique restored expression of FMR1 and, consequently, FMRP protein 114 . Unfortunately, phenotypic reversal was not assessed in this study.
Timothy Syndrome. Timothy syndrome is much rarer than fragile X syndrome, but also often results in syndromic ASD. The condition is caused by a mutation in the CACNA1C gene, which encodes an L-type voltage-gated calcium channel. The mutation reduces calciumdependent and voltage-dependent inactivation of the channel, which are forms of negative feedback regulation after membrane depolarization. Calcium channels have an important role in neuronal development because they control dendritic growth and arborization, and excessive calcium entry owing to the loss of feedback regulation has detrimental effects on brain development and growth.
Box 2 | X chromosome inactivation
In individuals with two X chromosomes, transcriptional silencing of one of the X chromosomes is required to avoid duplication of gene expression, a process commonly known as X-chromosome inactivation that is thought to be required for normal embryonic development. The process is mediated mainly by the large noncoding RNA X-inactive specific transcript (Xist), which coats the X chromosome in cis, thereby mediating transcriptional silencing of X-linked genes and inducing repressive chromatin character along the entire chromosome 182 . The maternal and paternal X chromosomes have equal chances of being silenced in the random process 183 . Interestingly, X-chromosome inactivation in XX hiPSCs has been shown to be nonrandom 184 . X-chromosome inactivation, which is retained in hiPSCs, presents a powerful addition to the potential of hiPSCs to model X-linked neurodevelopmental disorders such as Rett syndrome. For example, hiPSCs lines with a mutation in an X-linked gene and lines with the wild-type form of that gene can be derived from the same heterozygous individual. Both lines consequently have the same genetic background, making the wild-type form an isogenic control.
To date, the only neurodevelopmental disorders in which this phenomenon has been exploited in this way is LeschNyan syndrome 185 and Rett syndrome 82, 84, 94 . However, such an experimental design might not be as powerful as it initially seems. Although matched genetic backgrounds provide more statistical power, family studies are still more informative, as they enable comparisons to be made between the functional effects of mutated alleles in different genetic backgrounds. Additionally, caution is required because XX hiPSCs undergo progressive erosion of the pattern of X-chromosome inactivation with repeated passaging, with associated transcriptional derepression of genes on the inactive X chromosome 185 .
Tyrosine hydroxylase
An enzyme that converts the amino acid tyrosine to the dopamine precursor, DOPA.
PSD95-protein
Postsynaptic density protein 95 (involved in signalling).
An hiPSC-based model of Timothy syndrome has shown that neurons derived from patients with the condition exhibit impaired calcium signalling, abnormal electrophysiological properties, and defects in activity-dependent transcription 115 . Interestingly, expression of tyrosine hydroxylase was high in these neurons, which increased their production of noradrenaline and dopamine. hiPSCs derived from these patients had abnormal differentiation tendencies, and differentiated neurons had low expression of gene markers of the lower cortical layers and callosal projection neurons. In a subsequent study, a bioinformatics approach, in which coexpression network analysis and transcriptionfactor-binding analysis were combined, was used to determine that the dysregulated calcium signalling changes levels of calcium-dependent transcriptional regulators (NFAT, MEF2, CREB, and FOXO) and leads to the transcriptional network changes observed in neurons derived from patients with Timothy syndrome 116 . Another study indicated that hiPSC-derived neurons from individuals with Timothy syndrome have activity-dependent dendrite retraction 117 . Promisingly, the two groups that conducted these studies were able to reverse some deficits in neurons derived from patients with Timothy syndrome -one via treatment with roscovitine, an L-type voltage-gated calcium channel blocker 115 , and the other via overexpression of a relevant channel protein 117 .
Complex genetic disorders
hiPSCs have proved useful for modelling monogenic disorders, but their real power lies in their ability to model complex genetic disorders, in which multiple genes and multiple genetic backgrounds typically influence disease pathogenesis and for which engineering of a single penetrant mutation into an ESC line or rodent is not informative. The approach to modelling complex genetic disorders with hiPSCs has been to analyse gene expression and phenotype in a sufficient number of patient-derived and control lines to obtain mechanistic insights into the disorder (Supplementary information S1 (table) ). In these studies, the choice of patients and controls, the design of the study and the clinical phenotyping are critical.
Schizophrenia. Schizophrenia is a highly heterogeneous and complex disorder that can involve hallucinations, delusions and disorganized thinking (type 1), or cognitive deficits and disturbances in social and affective functions (type 2) 118 . The cause has classically been thought to be the interaction of predisposing genes with environmental factors. However, some estimates of heritability are as high as 80%, with a sibling recurrence risk ratio of 8.6 (REF. 16 ). Consequently, we focus on the genetic component in this section and discuss modelling of environmental factors later in the article (see Environmental factors).
Classification of schizophrenia as a developmental disorder is based on evidence that several perturbations during pregnancy increase the risk, and that genetic and epigenetic factors associated with schizophrenia point to disturbances of early cortical development 119, 120 . In particular, schizophrenia-associated DNA methylation is closely related to cellular and transcriptomic changes that occur during the transition between prenatal and postnatal life 121 . Neuropathological studies have revealed that patients with schizophrenia have lower brain volume, neuronal cell size and dendritic spine density than healthy controls, and abnormal neuronal distribution in the prefrontal cortex and hippocampus [122] [123] [124] [125] [126] . Furthermore, pharmacological studies have shown that NMDA receptor antagonists, such as ketamine and phencyclidine, can cause psychotic and cognitive abnormalities that resemble schizophrenia, indicating that reduced glutamate signalling is involved in the disorder [127] [128] [129] . The first hiPSC model of schizophrenia was generated in a study published in 2011 (REF. 130 ), the findings of which echoed many previous neuropathological and pharmacological studies by identifying diminished neuronal connectivity and low neurite numbers, PSD95-protein levels and glutamate receptor expression. However, the model also revealed new information about the cellular pathways involved: neurons derived from patients with schizophrenia exhibited abnormal expression of components of the cyclic AMP and Wnt signalling pathways 130 . The same researchers subsequently showed that NPCs derived from patients with schizophrenia exhibited aberrant migration, high oxidative stress, and perturbed responses to environmental stresses 131 . A separate study by the same group suggested increased protein synthesis owing to high levels of translation and high levels of elongation factor proteins in cultures derived from patients with schizophrenia, hinting at another possible mechanism of disease 56 . Other hiPSC models of schizophrenia have demonstrated further cellular and molecular elements of the disorder's pathogenesis that were undetectable with postmortem, genetic or neuroimaging studies, including
Box 3 | CRISPR-Cas
Genome engineering techniques enable researchers to edit endogenous sequences of DNA, and thereby to modulate expression of genes. The latest genome engineering technology, known as CRISPR-Cas, was discovered through studies of the prokaryotic immune system. Bacteria and archaea have a unique adaptive immune system in that they use RNA-guided enzymes to cleave and destroy foreign DNA. Prokaryotes can integrate pieces of foreign DNA (usually from invading viruses) into their own DNA into spacer regions. These spacer regions are regularly interspaced throughout the prokaryote's DNA and serve as a memory of previous invaders' DNA, thus enabling the development of acquired immunity. Spacer regions are preceded by short palindromic sequences, and the combination of the palindromic sequences and the spacer DNA are known as clustered regularly interspaced short palindromic repeats, or CRISPR. CRISPR sequences serve as the RNA-guide for DNA endonucleases known as CRISPR associated proteins, or Cas. These enzymes destroy foreign DNA, which they recognize via spacer regions of CRISPR.
In CRISPR-Cas systems, engineered CRISPR sequences are used as RNA guides for known Cas proteins in order to target specific regions of cellular DNA for endonuclease cleavage. Such cleaved DNA can be repaired via endogenous nonhomologous end joining, which creates small insertions or deletions that typically lead to alteration of the DNA reading frame, generating gene knockouts. Alternatively, Cas-cleaved DNA can be repaired by homologous recombination; in this case, the complementary strand is introduced experimentally in the cell, enabling precise editing of the DNA sequence. CRISPR-Cas enables the knockdown or editing of multiple genes simultaneously in a highly scalable fashion 186, 187 .
Macrocephaly
An abnormally large head circumference as a result of increased brain size; one of the most consistently replicated phenotypes in ASD, and associated with more-severe symptoms and poorer outcomes.
Canonical β-catenin-BRN2 cascade Intracellular signalling pathway triggered by the binding of Wnt (Wingless-related integration site) protein to its receptor, culminating with the translocation of the protein β-catenin into the nucleus to act as a transcriptional co-activator of transcription factors that belong to the TCF/ LEF family; the gene BRN2 is thought to be a transcriptional target for β-catenin.
Balanced translocation
Chromosomal abnormality in which two nonhomologous chromosomes exchange material in equal amounts (as opposed to unbalanced translocation where the amount of material exchanged is unequal).
abnormal microRNA expression profiles 132 , deficits in the polarity of adherens junction in apical cells of the brain ventricular layer 39 , and deficits in synaptic vesicle release 133 . Furthermore, a study in which patientderived hiPSCs were differentiated into dopaminergic and glutamatergic neurons revealed perturbations in neural differentiation and mitochondrial function 134 . Interestingly, some findings in hiPSCs and neurons derived from patients with schizophrenia are similar to those from hiPSC models of other disorders. For example, hiPSC-derived neurons in a model of schizophrenia exhibited L1 retrotransposition (which is also seen in Rett syndrome) 135 , and increased levels of tyrosine hydroxylase, with consequent increases in levels of catecholamines, dopamine, noradrenaline and adrenaline (as seen in Timothy syndrome) 136 , suggesting similarities between the pathologies of these neurodevelopmental disorders.
Autism spectrum disorder. Studies of rare exonic mutations have suggested that genes expressed during early fetal cortical development are implicated in the aetiology of ASD 137, 138 . In an effort to directly model early cortical development of patients with idiopathic autism, we produced hiPSC-derived telencephalic organoids from the fibroblasts of ASD patients with macrocephaly in (to our knowledge) the first published model of nonsyndromic, idiopathic ASD in which a phenotypic assessment was made 46 . Organoids were used to model early-fetal to mid-fetal telencephalic development in humans; the telencephalon gives rise to the cerebral cortex, hippocampus, basal ganglia and olfactory bulb. The telencephalic organoids contain both glutamatergic and GABAergic cortical neurons.
Gene network analyses of the transcriptomes of these organoids revealed upregulation of genes involved in cell proliferation, neuronal differentiation and synaptic assembly in ASD. Genes expressed by GABAergic neurons and their progenitors were strongly upregulated. Immunocytochemical analyses confirmed that organoids derived from patients with ASD exhibited an accelerated cell cycle and overproduction of GABAergic inhibitory neurons compared with organoids derived from the patients' unaffected parents. Use of RNA interference in the same study showed that increased expression of the master regulatory transcription factor FOXG1 is causallyinvolved in the increased production of GABAergic neurons in organoids derived from patients with ASD.
The data from this study are intriguing because the model mimics a very early stage of cortical development so would be expected to model a predisposition to disease, and this expectation was confirmed by finding a strong correlation between the expression changes in gene network modules and symptom severity in the small patient sample that participated in this study. One possible implication of the observed increase in GABAergic neurons and synaptic connections is that increased production of GABA aberrantly increases synaptogenesis, as GABA functions as an excitatory neurotransmitter promoting activity-dependent synapse formation in prenatal development 139 .
The increased levels of synapse-related transcripts observed in hiPSC-derived organoids echoes findings of a neuropathological study in which a morphological increase in synaptic connections was identified in un selected patients with idiopathic ASD 140 . Other studies have demonstrated increases in the density of cortical neuron minicolumns 141 and areas of aberrant cortical neuron layering 142, 143 in ASD, but no neuropathological studies have included sufficient samples to demonstrate an imbalance of inhibitory and excitatory neurons in the cortex. The increase in FOXG1 expression and the increase in GABAergic NPCs observed in the organoid model of idiopathic ASD with macrocephaly has been replicated in an independent study in which a non-organoid neuronal differentiation protocol was used 144 , consolidating the idea that FOXG1-mediated GABAergic disturbances are involved in ASD and suggesting that hiPSC modelling is robust and can yield reproducible data across hiPSC lines, patients and laboratories. The same study 144 also showed that a paradoxical reduction in the level of the Wnt signalling pathway (which, according to other studies, causes excessive proliferation of NPCs when overactive 145, 146 ) is related to the aberrant increase in proliferative activity in ASD with macrocephaly, as agents that increased the canonical β-catenin-BRN2 cascade normalized cell proliferation. Further evidence for an involvement of the Wnt signalling pathway in ASD is provided by the observation that ASD patients have mutations in CHD-8, a negative regulator of the canonical Wnt signalling pathway 17, [147] [148] [149] . In other studies, hiPSCs have been generated with specific mutations that have been associated with ASD in rare cases and have variable penetrance. In one of these studies 150 , hiPSCs and neurons were derived from an individual with nonsyndromic ASD with a de novo balanced translocation of TRPC6, a cation channel that has a fundamental role in calcium homeostasis. The group showed that these hiPSC-derived neurons with TRPC6 disruption had shorter and less arborized neurites, lower densities of dendritic spines and VGLUT1 puncta, and impaired sodium and calcium currents when compared with wild-type neurons. Restoration of TRPC6 expression or treatment with IGF1 or hyperforin (a TRPC6 agonist) partially corrected these abnormal phenotypes.
In one notable study that used a different approach to others, CRISPR-Cas9 technology was used to engineer hiPSCs that were heterozygous for a loss-of-function mutation of CDH8, which encodes an ATP-dependent chromatin remodelling protein that is strongly associated with ASD in rare cases. The mutation caused differential expression (compared with wild-type) of thousands of genes enriched in gene ontology functions, including β-catenin-Wnt signalling, demonstrating the combined power of genome engineering and hiPSC modelling 151 . This area of study is still emerging, and it will be interesting to see whether common pathophysiological mechanisms underlying ASD will emerge from these studies.
Several copy-number variations have been identified in patients with ASD [152] [153] [154] [155] [156] , but few have been modelled with hiPSCs. Of particular interest is an association of de novo duplications of the 7q11.23 region with ASD; deletion of the same region causes Williams-Beuren syndrome, which is characterized by increased sociability 157 . An hiPSC model of Willliams-Beuren syndrome has shown that NPCs in this condition have slow doubling times and high levels of apoptosis, and neurons have more dendritic spines and synapses than wild-type neurons 158 , as well as prolonged repolarization times and deficiencies in voltage-activated K + currents 159 .
Environmental factors
The models described in the previous sections exploit the ability of hiPSCs to be differentiated into neurons while retaining the unique genetic signature of the individual from whom they were derived, thereby replicating the developmental trajectory of an individual's brain development on the basis of their genetic code. However, neurodevelopmental disorders can be influenced by environmental factors as well as genetics. hiPSCs alone offer little or no insight into the macroenvironmental component of the pathogenesis of neurodevelopmental disorders, such as organism-level effects -for example, hormones and sensory experiences. By contrast, so-called microenvironmental effects can be studied in hiPSC-based organoid systems; the fact that the transcriptome and epigenome are dynamically altered by the cellular microenvironment is well known. Effects that can be modelled include cell-to-cell interactions, the effects of age, and the effects of diffusible substances generated by developing cells. hiPSC organoid systems could, for example, be exposed to toxic chemicals or immune challenges that mimic detrimental environmental effects to study the consequences on development.
One example of modelling a neurodevelopmental disorder driven by environmental factors is the use of brain organoids to model Zika virus infection. Such modelling of infection in the early embryonic stages can be useful in predicting problems later in life. hiPSCs have enabled investigation of aspects of Zika virus infection that could not previously be studied, such as the target of Zika virus that results in birth anomalies, such as microecephaly, and later problems with brain development that can lead to intellectual impairment, seizures, visual and hearing impairment, and others. In the short time since Zika virus became a critical public health concern, hiPSC modelling has enabled researchers to isolate exactly why the infection causes microcephaly. Tang et al. 160 showed that the virus readily infects forebrain-specific cortical NPCs, the building blocks of the human cortex. The same study showed that infection of NPCs results in downregulation of genes involved in regulation of the cell cycle, and upregulation of genes involved in apoptosis. Further evidence from this study and others indicated abnormal progression of the cell cycle, increased apoptosis, and disrupted neurogenesis [161] [162] [163] [164] [165] [166] [167] . An in-depth overview of the subject is available elsewhere 168 . These hiPSC models of Zika virus infection demonstrate the power of hiPSC modelling in understanding environmental influences, particularly how these influences manifest at the cellular and molecular level and lead to the pathogenesis of the disorder, and we strongly believe that more work should be done in this area.
Conclusions
To date, hiPSC model systems have not only confirmed previous findings about the pathogenesis of neuro developmental disorders, but provided further detail and shed light on the mechanisms that underlie the manifestations. Altered synaptic connectivity and density, an imbalance of excitation and inhibition, and altered neuronal activity had all been proposed as factors in neurodevelopmental disorders on the basis of postmortem, neuroimaging and genetic studies, and hiPSC models have often been able to establish the level of causality for these mechanisms because they enable experimental manipulation of the system. These causal relationships have been used to successfully reverse some abnormal phenotypes. Furthermore, hiPSCs have demonstrated the timing of phenotypic alterations, the events that lead to their first occurrence, and how they progress, whereas postmortem studies enabled examination of a single time point, often remote from the genesis of the disorder. Some phenotypic observations, such as neuron size and detailed spine morphology, that have been made in patient-derived neurons are entirely novel and were previously unobservable. Nevertheless, we think much is left to be discovered, especially in using hiPSCs to generate non-neuronal brain cells, which account for at least half of the total number of brain cells 169 . Additionally, work must be done to reduce the resources and time required for hiPSC studies so that more research groups can contribute to the field with studies that have high n numbers. One potential way to achieve this aim is to use protocols that involve direct conversion of somatic cells to neurons. However, the factors that are required for the determination and maintenance of defined neuronal types have not yet been completely elucidated, so use of these methods risks the creation of hybrid or otherwise nonphysiological neurons. Challenges also remain in fulfilling the translational potential of hiPSCs. An obvious difficulty is reproducing the cellular and regional complexities of the human brain. Another challenge is the fact that hiPSC-derived neurons often do not progress beyond the prenatal stage of maturation. These limitations and the complexity of these problems must be considered when trying to apply knowledge gained from hiPSC studies to patients.
Our long-term goal should be to make hiPSC-based drug discovery systems a reality. The field of tissue engineering has advanced considerably and, although the human brain is more difficult to model than peripheral tissue, keeping this long-term goal should help us to develop more sophisticated human neuron differentiation protocols. Such hiPSC-based drug discovery systems are already well on their way. In some cases, abnormal neurobiological phenotypes have already been reversed with existing drugs 74, 170, 171 . The predictive validity of this approach is likely to increase as the neurons used become more sophisticated and more representative of human neurons. Already, neurobiological phenotypes identified in patient-derived neurons have been used to conduct high-throughput genetic screens for compensatory mutations and potential drug targets [170] [171] [172] [173] [174] . By contrast, subtype characterization for clinical trials is currently done almost entirely through notoriously imprecise clinical diagnostic criteria. Gene network and neurobiological analyses of hiPSC-derived neurodevelopmental models could be used instead to identify subtypes on the basis of specific genes and pathways that are altered.
Another therapeutic avenue that could be explored with hiPSCs is transplantation. This approach is already adopted in clinical trials for some adult neurological disorders, such as macular degeneration 175 . However, we believe that the technique is challenging to use in disorders of childhood, particularly neurodevelopmental disorders in which little evidence exists for neuronal loss or neural tissue damage that necessitates regeneration. Nevertheless, the idea of editing mutations in patientderived hiPSCs and subsequently transplanting the cells back into the patient is exciting because transplantation is normally accompanied by the risk of host rejection; this risk would be negated with the use of hiPSCs, as the cells are derived from the patient themselves.
All of these areas of growth will require collaboration between multiple scientific and engineering disciplines. As we move from studying single genes and single mutations to studying networks that integrate the two, we will require collaboration between neurobiologists, bioinformaticians, statisticians and computer scientists. As we move to push the use of hiPSC modelling into the translational space, we will require not only the expertise but also the support of clinicians. 
